|
A mid-chemoradiation dynamic risk model integrating tumor features and ctDNA analysis for lung cancer outcome prediction. |
|
|
No Relationships to Disclose |
|
Mohammad Shahrokh Esfahani |
No Relationships to Disclose |
|
|
Patents, Royalties, Other Intellectual Property - I have a patent pending related to immunomodulatory nucleic acids. (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Varian Medical Systems |
Speakers' Bureau - Varian Medical Systems |
Travel, Accommodations, Expenses - Varian Medical Systems |
|
|
Honoraria - AstraZeneca; Bristol-Myers Squibb |
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb |
Research Funding - Abbvie; Celgene; United Therapeutics; Varian Medical Systems; Verily |
|
|
Consulting or Advisory Role - Drishti |
|
|
Consulting or Advisory Role - AstraZeneca; G1 Therapeutics; Pfizer |
Research Funding - Bayer (Inst); Boehringer Ingelheim (Inst); EpicentRx (Inst); Forty Seven (Inst) |
|
|
Honoraria - Biomedical Learning Institute; CME Matters; Medscape; MJH Life Sciences; MLI Peerview; Prime Oncology; Research to Practice; Rockpointe |
Consulting or Advisory Role - AstraZeneca; Calithera Biosciences; Exelixis; Genentech/Roche; Jounce Therapeutics; Lilly; Takeda |
Research Funding - Adaptimmune (Inst); Boehringer Ingelheim (Inst); Exelixis (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Takeda (Inst) |
Patents, Royalties, Other Intellectual Property - Up To Date - Royalties |
|
|
|
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Helsinn Therapeutics; Janssen Oncology; Mirati Therapeutics; Xcovery |
Research Funding - ACEA Biosciences (Inst); Arrys Therapeutics (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Exelixis (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Merck (Inst); Novartis (Inst); Pharmacyclics (Inst); Xcovery (Inst) |
Travel, Accommodations, Expenses - AstraZeneca |
(OPTIONAL) Uncompensated Relationships - Genentech/Roche; Merck; Takeda |
|
|
Stock and Other Ownership Interests - TibaRay, Inc. |
Honoraria - Varian Medical Systems |
Research Funding - RaySearch Laboratories; Varian Medical Systems |
|
|
Honoraria - AstraZeneca/MedImmune |
Speakers' Bureau - Varian Medical Systems |
Research Funding - Genentech/Roche; Hitachi Chemical; New River Labs; STCube Pharmaceuticals Inc. |
|
|
Leadership - Lymphoma Research Foundation |
Stock and Other Ownership Interests - CAPP Medical; CiberMed; Forty Seven |
Honoraria - Janssen Oncology; Janssen Oncology; Roche |
Consulting or Advisory Role - Celgene; Gilead Sciences; Roche/Genentech |
Research Funding - Celgene |
Patents, Royalties, Other Intellectual Property - Patent filings on ctDNA detection, assigned to Stanford University. (Inst) |
Travel, Accommodations, Expenses - Gilead Sciences; Roche |
|
|
Stock and Other Ownership Interests - CiberMed |
Consulting or Advisory Role - AstraZeneca; BioNTech; Roche |
Research Funding - Varian Medical Systems |
Patents, Royalties, Other Intellectual Property - Patent filings on ctDNA detection assigned to Stanford University (Inst); Patent filings on tumor treatment resistance mechanisms assigned to Stanford University (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Roche; Varian Medical Systems |